ArticlePain practice : the official journal of World Institute of Pain2025
Greater Occipital Nerve Block as Preventive Treatment in Migraine: A Time-To-Event Analysis.
Article in Pain practice : the official journal of World Institute of Pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultrasound-Guided Greater Occipital Nerve Block Across Headache Phenotypes: Outcomes and Determinants of Response in a Prospective Cohort.Pain and therapy · 2026Article
- Long-term efficacy and predictors of response to greater occipital nerve pulsed radiofrequency in migraine with prior preventive treatment failure.Acta neurologica Belgica · 2026Article
- Comparative study of greater occipital nerve block and conventional therapy in chronic migraine.Bioinformation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGreater occipital nerve block (GON-B) may still represent a valuable strategy in migraine prophylaxis despite the development of newer drugs. The absence of a standardized method leads to variable outcomes and limits its use. In this light, we investigated GON-B effects in a migraine population trying to define its duration and response predictors.
methodsIn this real-world study, we recruited patients with migraine who underwent bilateral GON-B. They were clinically evaluated at baseline and then monthly for the next 3 months, using a 30-day headache diary. The potential role of baseline headache characteristics in predicting treatment response was thoroughly analyzed.
resultsA total of 73 patients were enrolled: 50 (68%) were affected by chronic migraine while 38 (52%) by medication overuse headache (MOH). The greatest clinical benefit due to GON-B was reported during the first month, although the therapeutic response was substantially maintained during follow-up. Notably, similar outcomes were recorded in patients with and without MOH. The mean duration of effect was 55.3 ± 72.0 days, with no clinical variables significantly influencing this parameter. The therapeutic response seemed to be stronger in patients with migraine with aura.
conclusionsGON-B appears an effective option in migraine prophylaxis, even in difficult-to-treat patients. Its rapid effect, high tolerability, and cost-effectiveness represent indisputable advantages. A prolonged duration of action, which could be favored by the combination of anesthetic and steroid and needs to be confirmed in future studies, may further optimize patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.